THURSDAY, FEBRUARY 11

6:45 p.m.-7:00 p.m.  Welcome and Introduction
Elite Hall B

7:00 p.m.-8:00 p.m.  Keynote Address
Elite Hall B

The proteogenomics of breast cancer patient-derived xenografts
Matthew J. Ellis, Baylor College of Medicine Cancer Center, Houston, TX

8:00 p.m.-9:30 p.m.  Opening Reception
Elite Hall A

FRIDAY, FEBRUARY 12

7:00 a.m.-8:00 a.m.  Continental Breakfast
Elite Hall Foyer

8:00 a.m.-9:00 a.m.  Plenary Session 1: Biotechnology and International Efforts to PDX Model Development and Utilizations I
(not eligible for CME credit)
Elite Hall B

Introduction to the EuroPDX Consortia
Sergio Roman-Roman, Institute Curie, Paris, France
Patient-derived xenografts as translational tools to predict patient responses to oncology therapy
David Sidransky, Johns Hopkins Medical Institutes, Baltimore, MD

9:00 a.m.-10:30 a.m.  Workshop 1: PDX Development I
Elite Hall B

Lgr5 stem cell-based organoids in human disease
Hans Clevers, Hubrecht Institute, Sciences & University Medical Centre Utrecht, and Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands
PDX in colorectal cancer and carcinoma of the anal canal
Virginie Dangles-Marie, Institute Curie, Paris, France
Patient-derived orthotopic xenografts (PDOX): Better mimic the patient than subcutaneous xenografts
Robert M. Hoffman, AntiCancer, Inc., San Diego, CA

(not eligible for CME credit)

10:30 a.m.-10:45 a.m.  Break
Elite Hall Foyer
CONFEREE PROGRAM

10:45 a.m.-12:15 p.m. Workshop 2: PDX Development II
Elite Hall B
Patient-derived tumor xenografts for genotype-drug response correlations in colorectal cancer
Livio Trusolino, University of Torino School of Medicine, Candiolo Cancer Institute – IRCCS, Candiolo, Italy
Heterogeneous data management and integration for living biobanks
Andrea Bertotti, University of Torino School of Medicine, Candiolo Cancer Institute – IRCCS, Candiolo, Italy
Panel Discussion

12:30 p.m.-3:30 p.m. Poster Session A/Lunch
Elite Hall A

3:45 p.m.-5:15 p.m. Plenary Session 2: Disease-specific PDX Models I
Elite Hall B
Expression profiling of colorectal cancer PDX models for disease stratification and tumor-stroma interaction analysis
Enzo Medico, University of Torino School of Medicine, Candiolo Cancer Institute – IRCCS, Candiolo, Italy
Renal cancer tumourgrafts: A validated model to evaluate novel targeted therapies
James B. Brugarolas, UT Southwestern Medical Center, Dallas, TX
Ovatars in preclinical drug development and clinical trials for ovarian cancer patients
S. John Weroha, Mayo Clinic, Rochester, MN

5:15 p.m.- Evening off/Dinner on own

SATURDAY, FEBRUARY 13

7:00 a.m.-8:00 a.m. Continental Breakfast
Elite Hall Foyer

8:00 a.m.-9:00 a.m. Plenary Session 3: Biotechnology and International Efforts to PDX Model Development and Utilizations II
(not eligible for CME credit)
Elite Hall B
NCI’s patient-derived cancer models repository
James H. Doroshow, NCI-DCTD, Bethesda, MD
The Jackson Laboratory PDX collection
Edison T. Liu, The Jackson Laboratory, Bar Harbor, ME

12 PATIENT- DERIVED CANCER MODELS
9:00 a.m.-10:30 a.m.  
**Plenary Session 4: Disease-specific PDX Models II**  
Elite Hall B

PDX models in head and neck cancers: Present status and future application for immune-oriented biology and therapy development  
Antonio Jimeno, University of Colorado Cancer Center, Aurora, CO

Promise and challenges of pediatric cancer PDX models  
Peter J. Houghton, Greehey Children’s Cancer Research Institute, San Antonio, TX

Patient-derived xenograft models in glioblastoma  
Joan Seoane, Vall d’Hebron Institute of Oncology, Barcelona, Spain

10:30 a.m.-10:45 a.m.  
**Break**  
Elite Hall Foyer

10:45 a.m.-11:45 a.m.  
**Plenary Session 5: Disease-specific PDX Models III**  
Elite Hall B

Application of PDX models to pancreas cancer research  
Manuel Hidalgo, Beth Israel Deaconess Medical Center, Boston, MA

Title to be announced  
Jeffrey A. Engelman, Massachusetts General Hospital, Boston, MA

11:45 a.m.-1:45 p.m.  
**Lunch on own**

1:45 p.m.-3:45 p.m.  
**Plenary Session 6: Practical Applications of PDX Models**  
Elite Hall B

Phase II human clinical trials in mice-modeling inter-patient response heterogeneity in PDXs  
Hui Gao, Novartis Institutes of Biomedical Research, Cambridge, MA

Challenges, opportunities, and lessons learned in the bench-to-bedside translation of xenopatient studies  
S. Gail Eckhardt, University of Colorado Cancer Center, Aurora, CO

Opportunities for integration of PDX models into clinical trials  
Scott Kopetz, The University of Texas MD Anderson Cancer Center, Houston, TX

Studying drug resistance through PDX models  
Maurizio Scaltriti, Memorial Sloan Kettering Cancer Center, New York, NY
3:45 p.m.-4:45 p.m.   Spotlight on Proffered Papers Session  
Elite Hall B

Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell and patient-derived tumor organoids*  
Senthil K. Muthuswamy, Beth Israel Deaconess Medical Center, Boston, MA

Humanized mouse melanoma model using patient-derived xenografts*  
Clemens Krepler, The Wistar Institute, Philadelphia, PA

Characterizing the immune context of responses to immunotherapy in humanized patient derived xenograft models of CRC*  
Anna Capasso, University of Colorado, Denver, CO

Integration of CRISPR-Cas9, RNAi, and pharmacologic screens identify actionable targets in a rare cancer*  
Andrew Lee Hong, Dana-Farber Cancer Institute, Boston, MA

A 3D image-based phenotypic screen of bi-specific antibodies targeting stem cells in a panel of patient derived colon carcinoma organoids*  
Bram Herpers, OcellO B.V., Leiden, The Netherlands

Conditional reprogramming is successful in generating patient-derived stable cell cultures from rare aggressive tumors*  
Seema Agarwal, Georgetown University, Washington, DC

*not eligible for CME credit

4:45 p.m.-7:15 p.m.   Poster Session B/Reception  
Elite Hall A

7:15 p.m.- Evening off/Dinner on own

SUNDAY, FEBRUARY 14

7:00 a.m.-8:00 a.m.   Continental Breakfast  
Elite Hall Foyer

*Short talks from proffered abstracts
8:00 a.m.-10:00 a.m.   Plenary Session 7: Patient-derived In Vitro Models
Elite Hall B

Organoid models of pancreatic cancer
David A. Tuveson, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York

Organoid cultures from patients with prostate cancer
Yu Chen, Memorial Sloan Kettering Cancer Center, New York, NY

Establishment of a colorectal tumor organoid library to model human colorectal cancer
Toshiro Sato, Keio University School of Medicine, Tokyo, Japan

Conditionally Reprogrammed Cells (CRCs): A simple, two-component cell system for basic and clinical cancer research
Richard Schlegel, Georgetown University Medical School, Washington, DC

10:00 a.m.-10:15 a.m.   Break
Elite Hall Foyer

10:15 a.m.-11:00 a.m.   Roundtable Discussion: PDX vs. GEMM vs Organoids
(not eligible for CME credit)
Elite Hall B

PDX models vs GEMMs vs organoids in breast cancer
Jos Jonkers, Netherlands Cancer Institute, Amsterdam, The Netherlands

Panelists:
S. Gail Eckhardt, University of Colorado Cancer Center, Aurora, CO
Jos Jonkers
Senthil K. Muthuswamy, Beth Israel Deaconess Medical Center, Boston, Massachusetts
Richard Schlegel, Georgetown University, Washington, DC
Livio Trusolino, University of Torino School of Medicine, Candiolo Cancer Institute – IRCCS, Candiolo, Italy
David A. Tuveson, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY

11:00 a.m.-12:30 p.m.   Plenary Session 8: Innovative Approaches to PDX Model Generation
Elite Hall B

Small cell lung cancer circulating tumor cell-derived explants – A new preclinical platform for examining drug response
Kris Frese, Cancer Research UK Manchester Institute, Manchester, England

Innovative PDX models for studying immunotherapy of cancer
Miguel F. Sanmamed, Yale University, New Haven, CT

Mice host selection for model development
Edison T. Liu, The Jackson Laboratory, Bar Harbor, ME

12:30 p.m.   Adjourn